Tirzepatide

Tirzepatide is a dual GLP-1 and GIP receptor agonist peptide of significant interest in metabolic research. Its dual incretin mechanism — simultaneously targeting both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors — makes it a widely studied reference compound for investigating glucose metabolism, insulin signalling, and energy homeostasis in laboratory models.

Areas of Interest

Laboratory studies of Tirzepatide have investigated a variety of promising areas:

• •Dual incretin receptor pharmacology — studied as a tool for understanding coordinated GLP-1 and GIP receptor activation and their combined effects on insulin secretion and metabolic regulation.
• •Glucose-dependent insulin secretion — examined in cellular models for its effects on insulinotropic signalling, beta-cell function, and glucose-stimulated insulin release.
• •Energy homeostasis & metabolic regulation — investigated for downstream effects on energy balance, substrate partitioning, and metabolic adaptation in preclinical research models.
• •GIP- and GLP-1-mediated signalling cascades — explored for intracellular signalling pathway activation, including cAMP/PKA, MAPK/ERK, and beta-arrestin recruitment in receptor-specific cell lines.
• •Comparative incretin pharmacology — used as a dual-agonist reference for comparative studies with single-agonist (GLP-1) and triple-agonist (GLP-1/GIP/GCG) compounds in binding affinity and functional assay panels.

Our Tirzepatide is supplied as a lyophilized powder with a purity of ≥99.1%, verified by HPLC and mass spectrometry. Each batch is accompanied by a Certificate of Analysis documenting sequence identity, molecular weight confirmation, and chromatographic purity.